Orexo AB (publ) Inactive USPTO patents

Utility

Pharmaceutical Composition Comprising Adrenaline

9 Nov 23

Jonas SÄVMARKER, Robert RÖNN

Filed: 24 May 23

Utility

New Pharmaceutical Device for Use In Intranasal Administration

5 Oct 23

Jonas SÄVMARKER, Robert RÖNN

Filed: 24 May 23

Utility

k9455dwxfmncum1k82bqd1at5196qotm2oibrd5lko2bpotlnh8xr

4 Apr 23

The present disclosure is directed to a method of combatting opioid dependence in a subject experiencing a depressive episode.

Michael John Sumner

Filed: 30 Jun 21

Utility

lgyxkybdrfph5rd2jybdzoli7rb3xkr30y4uz9je6w1d0idxi2tt0512qa

6 Sep 22

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.

Andreas Fischer

Filed: 25 Sep 20

Utility

owjg3movvd4fnu94fy95g9 mkd2xbr0szm1ninifbpho9esi8n1h4

24 Mar 22

Jonas SÄVMARKER, Robert RÖNN, Andreas FISCHER

Filed: 2 Dec 21

Utility

vojx8klc0uecfpdqc2yhh5so6zpk zi3rvk5ap5te3r0gfa7ol8wxr

30 Dec 21

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier.

Jonas Sävmarker, Robert Rönn, Andreas Fischer

Filed: 10 Feb 21

Utility

0qzwkswsn8dzv 7j64l0tj4uyzlwdb5tchvy

1 Jun 21

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.

Andreas Fischer

Filed: 25 Sep 20

Utility

xzgbrzl 8z0xbfapnbnngpc3s8ckxe68

1 Jun 21

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.

Andreas Fischer

Filed: 25 Sep 20

Utility

o8ny m555p9g5f5yw00iaw69b51ag6aat1tuf

16 Mar 21

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.

Andreas Fischer

Filed: 1 Sep 20

Utility

6ns3qmgacdav0fy4wcdwv8 a28

4 Feb 21

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.

Andreas Fischer

Filed: 25 Sep 20

Utility

7bqh9af3udrqf5ek kbo35pxykzc5nrz8ej4uf5p93a

26 Jan 21

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier.

Jonas Sävmarker, Robert Rönn

Filed: 27 Jul 20

Utility

yfrz414bg2q6cb6up767q17lgcobf90ig1t82icvpvg5jv5qz6ac59

14 Jan 21

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier.

Jonas Sävmarker, Robert Rönn, Andreas Fischer

Filed: 27 Jul 20

Utility

d2le2zkxdtejdvr09hnzkd 2un163p7b4kbn5u9gtavg8mr

14 Jan 21

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier.

Jonas Sävmarker, Robert Rönn, Andreas Fischer

Filed: 27 Jul 20

Utility

9hjjjmq0j4rcstmyaad0upwlsw54d

14 Jan 21

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.

Andreas Fischer

Filed: 25 Sep 20

Utility

lrtacz z2ldr8jrts2sbzr0n3bfn

14 Jan 21

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.

Andreas Fischer

Filed: 25 Sep 20

Utility

qztcystdgg3vj1afqoj2

28 Dec 20

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.

Andreas Fischer

Filed: 30 Jul 18

Utility

9hovjycbsswudwps2661mnko3zsiy 2038iyqd2kqxpb21bcep9nmec2j

23 Dec 20

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.

Andreas Fischer

Filed: 31 Aug 20

Utility

4z5f2iuiv58wd3uqlqvzo9xui5rizx5saydowa lllft42icsa9gsc2gfj

3 Aug 20

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier.

Jonas Sävmarker, Robert Rönn, Andreas Fischer

Filed: 17 May 20

Utility

jlxvkrqmnisy3vg i2bkzyf6unb3p7npsuuy49sbw0

18 May 20

There is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist.

Jonas Sävmarker, Robert Rönn, Andreas Fischer

Filed: 8 Jul 19